Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adenosine triphosphate + glycine propionyl-L-carnitine
- Development stage
- Unknown
- Lead developer
- Sigma Tau Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The combination of adenosine triphosphate (ATP) and glycine propionyl-L-carnitine (GPLC) is a dietary supplement formulation primarily utilized as an ergogenic aid to enhance athletic performance and muscular power. Adenosine triphosphate, typically provided as disodium ATP, acts as an extracellular signaling molecule that binds to purinergic P2Y receptors on the vascular endothelium, triggering the release of nitric oxide and prostacyclins to induce vasodilation and improve blood flow to active tissues. Glycine propionyl-L-carnitine is a molecularly bonded form of propionyl-L-carnitine and the amino acid glycine; it serves to increase endogenous nitric oxide levels and facilitate the transport of long-chain fatty acids into the mitochondria for beta-oxidation. Together, these compounds are marketed to improve peak power output, increase total training volume, and reduce exercise-induced oxidative stress and fatigue.
- Brand names
- PEAK ATP
- Other names
- ATP + GPLCadenosine 5-triphosphate + glycine propionyl-L-carnitine
02
Targets
NOS1 (nNOS)P2RY2 (P2Y Purinoceptor 2)
Beyond the preview
Go deeper on adenosine triphosphate + glycine propionyl-L-carnitine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adenosine triphosphate + glycine propionyl-L-carnitine.